ABSTRACT
SPECIFIC POLYMORPHISM 4G/5G GENE FOR PAI1 AS A POSSIBLE CAUSE OF CEREBRAL VENOUS THROMBOSIS: A CASE REPORT

INTRODUCTION
Thrombosis of veins and venous sinuses (CVT) is a rare cerebrovascular disorder which makes less than 1% of all strokes (1) . With the adult patients there is an incidence of 3-4 cases per million (1), while in pediatric population it is bigger and it numbers 7 cases per million children per year (2) . This disorder is associated with the high risk of death outcome and significant rate of consequent mental disability. In addition, the distinctive variability concerning etiology and clinical manifestation, as well as disagreement in the approach of medical treatment, ranked CVT in the group of important public health problems, which is worldwide, even today, the real challenge from the diagnostic and therapy standpoint.
One of the most significant causes of CVT are congenital and acquired thrombophilia that occur at 29% of patients, 22% of which are hereditary hyper coagulate states (3). Congenital thrombophilia have particular importance from the diagnostic aspect, where genetic deficit of antithrombin III and protein C and S and also mutation of G169A factor of V coagulation (FV Leiden), gene for prothrombin (FII G20210A) and gene for methylenetetrahydrofolate reductase (MTHFR C677T), in earlier studies were identified as independent risk factors for the occurrence of CVT (3, 4) . On the other hand, for prothrombotic state due to genetic mutations in the plasminogen activator inhibitor 1 (PAI-1) there are no solid written evidence about the connection of such a disorder with risk of CVT, depending on polymorphism promoter region of PAI-1 gene.
In this case we present a young adult female patient with the thrombosis of sagittal venous sinus, who is confirmed to have the mutation of gene for PAI 1 5G/4G.
CASE REPORT
A female patient, 36 years old, was admitted in May 2015, at 6:50 PM at the Clinic of Neurology, Clinical Center Kragujevac, where she was sent from a regional hospital in Kosovska Mitrovica for the diffuse headache she had suffered for the past few days and one generalized tonic-clonic epileptic (GTC) seizure in the morning hours on the day of admission.
On admittance to our clinic, the patient was conscious, oriented, with stable vital parameters and with the finding of blood glucose in capillary blood (7,2 mmol/l) and the tongue bite as a confirmation of a previous epileptic seizure. In the neurological examination right-sided hemiparesis of the lower level was recorded with the score 5 on the National Institute of Health Stroke Scale (NIHSS).
In the personal anamnesis, the patient denied previous acute and other chronic diseases of importance. She had had three regular pregnancies with natural childbirths with no complications. She also denied diseases of hereditary significance.
Two more GTC seizures were observed right after the admittance of the patient. Computerized tomography of endo-cranium (CT) was initially performed where no pathological changes supratentorial and infratentorial were noticed. Anti-edematous therapy was immediately administered (Mannitol 20%, 125 ml/6 hours), anti-epileptic (Diazepam, intravenously, 10mg and tablets of Natrium-valproate in a fixed combination with valproic acid (333mg+145mg), daily dose 250mg/12 hours) and antiaggregation therapy (100mg acetylsalicylic acid/24 hours). After that, the cardiologist was consulted who registered normal findings of the observed physiological systems. Basic laboratory analyses were made (complete blood test, Creactive protein, glucose, urea, creatinine, jonogram) with the results within the limits of reference values.
The next morning, the patient was examined by magnetic resonance (MR cranial, MR venography and MR 2D venography) which confirmed the thrombosis of the upper and lower sagittal sinus, while high left in parietal lobe the signs of sub-acute ischemic lesions with hemorrhagic transformation were registered.
The second day of hospitalization, after the above mentioned additional radiological examinations, the therapy was changed in the sense that the suspended use of doze of acetylsalicylic acid and low molecular heparin, enoxaparin, in therapy doze 0,6 mg/12 hours, subcutaneously) was added. During the controlling neurological examination right-sided weakness persisted with the identical NIHSS as at the admittance to the hospital.
On the fifth day of hospitalization anti-edematous therapy was excluded and the appliance of anti-epileptics, natrium-valproate in the fixed combination with valproic acid was continued through the full therapeutic dose (500mg/12 hours).
During the further hospitalization ultrasound heart examination was done as well as color Doppler-sonography (CDS) of main neck arteries with positive results recorded.
Further laboratory tests were carried out with the aim to examine the cause of thrombosis, which meant to eliminate potential immunological and infective causes of a new neurological disorder: prothrombin and activated partial thromboplastin time were measured, concentration of D dimer and fibrin monomers, the activity of anti-thrombin and anticoagulant proteins C and S, the level of homocysteine, coagulation test with diluted Rusell's snake poison, lupus anticoagulant, activity and concentration of vonWilebrand's factor and the activity of coagulation factors II, V and VIII; also the level of immunoglobulin types G, M and A, activity of C3 and C4 components of complement, titer of anti-nucleus, anti-mitochondrial and anti-smooth muscles antibodies, then concentration of the surface antigen of hepatitis B virus and the titer of specific antibodies against hepatitis C virus, HIV virus, Epstein-Bar virus and Borrelia Burgdorferi; the results of all listed analyses were normaland the tolerances without clinical importance.
In order to additionally examine etiology of thrombosis, genetic searches were carried out also (real time PCR) to thrombophilia, which didn't confirm the mutation of gene for prothrombin (FII G20210A), factor V coagulation (FV Leiden) and methylenetetrahydrofolate reductase (MTHFR C677T), while simultaneously the existence of specific polymorphism 4G/5G(locus-675) in promote region PAI-1 gene was confirmed.
After two weeks of hospitalization, total regression of neurological deficit occurred and the patient didn't have epileptic seizures any more.
On discharge, instead of low molecular heparin, peroral anti-coagulant prophylaxis was added as therapy, tablets of dabigatran 150 mg/12 hours, with previously administered anti-epileptic therapy. During the routine three-month control tests after the discharge from the hospital, no neurological deficit was detected with the patient, she didn't have epileptic seizures, she was taking prescribed therapy regularly and she took it well.
DISCUSSION
Thrombosis of veins and venous sinus is picturesquely called "major neurological forger" considering that it is characterized by very diverse clinical picture. This disorder is noticed mainly with the persons younger than 50 (at about 80%), whereby 75% of cases are women (5) . It is often manifested by headache (6), eyesight disturbances (7), epileptic seizures (8), consciousness disorder and focal neurological deficit as well as specific symptoms depending on the localization of pathological process. When the thrombosis of sagittal sinuses is suspected according to the clinical picture, properly set diagnosis requires complete evaluation by neuro-visualization methods as CT or MR venography depending on availability and characteristics of the patient, which present the "golden standard" for the confirmation of this disorder (1). Our patient according to all demographic and clinical standards presents the typical example of CVT, for whom due to the inability of adequate CT confirmation, diagnosis of thrombosis of the upper sagittal sinus was set by MR venography.
Among various causes of CVT, which can be of infective (sinusitis, otitis media, meningitis, system infections,etc) or non-infective nature (trauma, brain tumors, certain neurosurgical procedures, hematological malignancies, pregnancy and postpartum period, consuming of some medications, chronic inflammatory bowels diseases, system diseases of connective tissue, nephritic syndrome, cirrhosis of the liver,etc), congenital hyper coagulopathy stands out, it's diagnosis is based on highly sophisticated diagnostic tests (9) . In the case of our patient, with appropriate laboratory tests, positive immunological and genetic analyses, disorders at the level and activity of the most factors which can influence the occurrence of vein thromboses, (prothrombine, anti-thrombin, anti-coagulation proteins C and S, factor V coagulation, methylenetetrahydrofolate reductase enzyme, anti-phospholipid antibodies,etc) were excluded while the determination of the specific polymorphism 4G/5G gene for PAI-1 was the only pathological result which indicated to the possible congenital thrombophilia.
Plasminogen activator inhibitor type 1 is an endogenous glycoprotein from the group of serine proteases, which is produced in endothelial cells, liver cells, fat, etc. (10) In the human body acts as the main inhibitor of a tissue plasminogen activator and urokinase, as a result of which a suppression of fibrinolytic activity occurs. (11) Its synthesis is regulated by the gene on chromosome 7 in whose promoter region at position -675 bp mutation is described which results in heterozygous variant of 4G/5G, with the 4G only transcriptionally active allelic variants responsible for increasing levels of PAI-1 in plasma, thus generally increases the risk of thrombosis (12) . A recent study in a population of patients in Serbia showed that the frequency of this polymorphism is the most frequent, with an incidence of slightly more than 46%, while the recorded prevalence of allelic variants of homozygous 4G/4G and 5G/5G was quite a range of about 36%, or 19% (13) .
According to previous studies, the effect of heterozygous variants of 4G/5G PAI-1 gene on the formation of arterial or venous thromboembolic complications is controversial. In fact, there is evidence that the presence of the 4G/5G polymorphism of PAI-1 can significantly increase the risk of coronary ischemic disease (14) , including myocardial infarct (15) , and venous thromboembolism (16, 17) , while on the other hand, there are data indicating the absence of any connection between the genotypic variants with the aforementioned unwanted outcomes (18, 19) . In addition, it was shown that in most cases the contribution of PAI-1 4G/5G polymorphism of the synergetic conditioned by the presence of other congenital and/or acquired conventional risk factors for the occurrence of arterial, and venous thrombosis, such as hypertension, diabetic disease, obesity, malignant diseases, chronic inflammatory diseases, hereditary hyper coagulopathy and similar (1-4), which also can have a significant impact on the level of PAI-1 in plasma. In contrast, none of the previous studies have established significant connection 4G/5G genotype and ischemic stroke (20, 21) . Moreover, in contrast to the thrombosis of the coronary arteries which is dominated by allelic variant 4G with the increase of PAI-1 in plasma, cerebral artery thrombosis is significantly associated only with the homozygous genotype 5G/5G, accompanied by a reduced plasma levels of PAI-1 (8) . This paradox suggests that specific polymorphism 4G/5G PAI-1 gene does not affect the mechanisms of cardiovascular risk solely dependent on the level of PAI-1 in plasma (8) . When it comes to CVT, according to our knowledge so far only one type has been carried out of observational study "case-control", which has not shown that allelic variant of 4G/5G PAI-1 gene significantly affects the risk of this disorder, unlike mutations of prothrombin G20210A (22) . *** Additionally, the PAI-1 4G/5G polymorphism was associated with the risk of the numerous and varied other clinical disorders such as diabetic mellitus and its chronic complications (23, 24) , recurrent miscarriage (25) , preeclampsia (26) , polycystic ovary syndrome (27) , bronchial asthma (28), cancer (especially colon and endometrium) (29) , sepsis (including fatal outcome as a result) (30) etc, where due to unreconciled opinions, further studies on this are carried out intensively.
CONCLUSION:
In the case of our patient the available screening and confirmatory diagnostic tests excluded all other potential causes of venous sinus thrombosis. To our knowledge,this is the first described patient with the history of specific polymorphism 4G/5G (locus-675) in the promoter region of PAI-1 gene isolated a possible cause of thrombosis of the sagittal sinus, which should be confirmed in future prospective studies of adequate design.
